Axsome Therapeutics (AXSM) Price/OCF Ratio: History & Chart

Axsome Therapeutics, Inc.(AXSM)

Biotechnology · New York City, NY

$175.19-1.90 (-1.07%)

Delayed quote: Oct 6, 2026, 2:00 PM EDT

About Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.

New York City, NY

1,346 employees

www.axsome.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Herriot Tabuteau

View full financials

NAME	MARKET CAP	PRICE/OCF RATIO	TTM	3Y	5Y
Axsome Therapeutics, Inc. (AXSM)	$9.01B	N/A	N/A	N/A	N/A
Bruker Corporation (BRKRP)vs ›	$8.98B	47.15	431.84	416.88	416.88
Protagonist Therapeutics, Inc. (PTGX)vs ›	$8.79B	66.98	93.91	51.23	51.23
Bruker Corporation (BRKR)vs ›	$9.27B	48.68	56.23	39.18	38.23
Arrowhead Pharmaceuticals, Inc. (ARWR)vs ›	$8.74B	N/A	89.68	89.68	63.13
Vaxcyte, Inc. (PCVX)vs ›	$9.34B	N/A	N/A	N/A	N/A
Insulet Corp. (PODD)vs ›	$9.38B	18.36	28.05	52.68	114.81
Kymera Therapeutics, Inc. (KYMR)vs ›	$8.58B	N/A	31.83	31.73	31.73
Krystal Biotech, Inc. (KRYS)vs ›	$9.57B	35.15	39.12	42.86	42.86
Oscar Health, Inc. (OSCR)vs ›	$8.36B	1.91	3.82	5.82	6.60

NAME

MARKET CAP

PRICE/OCF RATIO

TTM

Axsome Therapeutics, Inc. (AXSM)

$9.01B

N/A

Bruker Corporation (BRKRP)vs ›

$8.98B

47.15

431.84

416.88

Protagonist Therapeutics, Inc. (PTGX)vs ›

$8.79B

66.98

93.91

51.23

Bruker Corporation (BRKR)vs ›

$9.27B

48.68

56.23

39.18

38.23

Arrowhead Pharmaceuticals, Inc. (ARWR)vs ›

$8.74B

N/A

89.68

63.13

Vaxcyte, Inc. (PCVX)vs ›

$9.34B

N/A

Insulet Corp. (PODD)vs ›

$9.38B

18.36

28.05

52.68

114.81

Kymera Therapeutics, Inc. (KYMR)vs ›

$8.58B

N/A

31.83

31.73

Krystal Biotech, Inc. (KRYS)vs ›

$9.57B

35.15

39.12

42.86

Oscar Health, Inc. (OSCR)vs ›

$8.36B

1.91

3.82

5.82

6.60

Price/OCF Ratio Formula & Definition

P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.

Price/OCF Ratio: N/A

AXSM Price/OCF Ratio Metrics

AXSM Competitors' Price/OCF Ratio

Operating Cash Flow Valuation

Price/OCF Ratio Formula & Definition

Related Metrics